ASP ISOTOPES / QLE - SILICON-28 MONOPOLY: THE HIGHEST-MARGIN CHOKEPOINT IN QUANTUM MATERIALS

Jul 09, 2026

∙ Paid

SEQH CAPITAL RESEARCH - TEAR SHEET
ASP ISOTOPES / QLE - SILICON-28 MONOPOLY: THE HIGHEST-MARGIN CHOKEPOINT IN QUANTUM MATERIALS

WHAT THIS REPORT ARGUES

This note argues that silicon-28 is becoming one of the most strategically important isotope markets in advanced technology, and that ASP Isotopes may be moving into a near-monopoly position in Western supply.
SEQH’s core point is that the market is still treating silicon-28 as an obscure specialty product, when it may actually be a critical quantum-enabling material with unusually strong pricing power, limited competition, and very high margin potential.

Core thesis

The report frames silicon-28 as a chokepoint material for quantum computing and other next-generation applications, not just another isotope product inside the ASP portfolio.
Unlike broader isotope baskets, this market appears unusually concentrated because the technical difficulty of enrichment is high, qualification pathways are narrow, and end users care more about purity and continuity than about broad supplier choice.
SEQH’s conclusion is that if ASP can establish itself as the trusted commercial source of enriched silicon-28, the value of that position could be much larger than investors currently assign.

Silicon-28 matters because isotopically purified silicon reduces nuclear-spin noise, which makes it especially valuable for quantum computing architectures that rely on long coherence times.
That gives the material an unusually attractive demand profile: the volumes are relatively small, but the strategic value per kilogram can be extremely high because performance matters more than commodity cost.
The report appears to argue that this creates a market structure where a qualified supplier can capture economics that look closer to a technology monopoly than to a normal specialty-material business.

SEQH seems to argue that ASP’s edge comes from a combination of technical capability, timing, and lack of credible Western alternatives.
In this framing, the market is not asking whether silicon-28 demand exists, but whether anyone besides ASP can produce it at the right purity, in the right jurisdiction, and with the right commercial consistency.
That is what gives the report its monopoly language: not necessarily monopoly in a legal sense, but a practical monopoly created by capability, scarcity, and customer qualification barriers.

The note appears to connect the silicon-28 thesis to the broader QLE and isotope sovereignty narrative, arguing that ASP is gradually assembling a platform built around hard-to-replicate isotope positions rather than one-off niche products.
In that context, silicon-28 is important not only for its own economics, but because it strengthens the company’s identity as a Western strategic isotope supplier across both quantum and nuclear-linked markets.
SEQH’s broader message seems to be that ASP should be understood less as a speculative collection of science projects and more as a portfolio of isotope chokepoints with asymmetric strategic value.

The report appears to imply that silicon-28 could become one of the highest-margin products in the company’s portfolio because of low-volume, high-value demand and limited competitive pressure.
That matters because investors often undervalue businesses like this by using conventional materials logic, when the better framework may be scarcity pricing plus strategic dependency.
In other words, the upside is not just more revenue, but the possibility that ASP controls a product category where customers have very few acceptable substitutes.

SEQH seems to think the market still underestimates silicon-28 because it sits at the intersection of quantum technology, isotope enrichment, and sovereignty, which means no single investor group fully owns the story.
Quantum investors may overlook the enrichment bottleneck, while materials investors may not fully appreciate the end-market importance of isotopically pure silicon.
That information gap is what allows the opportunity to remain mispriced even as the strategic logic becomes clearer.

The cleanest way to read this note is that silicon-28 is not just an ASP product, but a potential monopoly-grade strategic asset.
SEQH is arguing that if ASP proves commercial scale, purity, and supply continuity, the market may eventually treat silicon-28 as one of the company’s most important value drivers rather than as a small specialty side business.

FULL 24-PAGE REPORT ON ASPI/QLE SILICON-28 CHOKEPOINT WITH EXTENSIVE PRICE MODELING AND FORECASTING ATTACHED BELOW: